Physician profile
Crystal Gerhardt
NPI 1114401932
$2,435.38
in general payments reported to CMS, 2019-2025
20 companies · $648 in 2025
The $648 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $534 · 2023: $289 · 2024: $684 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.03 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $550.46 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Lundbeck LLC | $292.43 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $267.78 | 2021-2025 | Rexulti, Abilify Mycite |
| Abbvie INC. | $217.51 | 2022-2025 | |
| Axsome Therapeutics, INC. | $173.10 | 2023-2025 | Auvelity |
| Corium, LLC | $146.20 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $121.83 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $113.05 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $90.20 | 2021-2022 | |
| Indivior INC. | $84.35 | 2024-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $80.46 | 2024-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.12 | 2023 | |
| Janssen Pharmaceuticals, INC | $65.72 | 2022-2025 | Invega Sustenna, Spravato |
| Braeburn INC. | $61.27 | 2024 | Brixadi |
| Bausch Health US, LLC | $27.29 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $17.61 | 2025 | |
| Lilly USA, LLC | $15.31 | 2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $15.15 | 2023 | Qelbree |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Brainsway USA INC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Gerhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.